Eric Venker - 03 Aug 2023 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
07 Aug 2023, 21:30:35 UTC
Prior SEC filing
02 Aug 2023
Next SEC filing
16 Aug 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jo Chen, as Attorney-in-Fact for Eric Venker

Key filing fact

Eric Venker filed Form 4 for Roivant Sciences Ltd. (ROIV) on 07 Aug 2023.

Key facts

  • This page summarizes Eric Venker's Form 4 filing for Roivant Sciences Ltd. (ROIV).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 07 Aug 2023, 21:30.

Change

  • Previous filing in this sequence was filed on 02 Aug 2023.
  • Current net transaction value: -$360,602.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ROIV transaction

Common Shares

Options Exercise

Transaction value
$171,822
Shares
+44,629
Change %
+7.1%
Price
$3.85
Shares after
672,547
Date
03 Aug 2023
Ownership
Direct
ROIV transaction

Common Shares

Sale

Transaction value
$532,424
Shares
-44,629
Change %
-6.6%
Price
$11.93
Shares after
627,918
Date
03 Aug 2023
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ROIV transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-44,629
Change %
-0.31%
Price
$0.000000
Shares after
14,583,389
Date
03 Aug 2023
Ownership
Direct
Underlying class
Common Shares
Underlying amount
44,629
Exercise price
$3.85
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.

Footnote F2

Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .